Key Takeaways
How Is Depression Cured? Remission Is the Clinical Goal
How is depression cured? Clinicians rarely use the word cure. Treatment aims for remission, meaning symptoms fall to a minimal level, and then for keeping them there.
NIMH says treatment for depression typically involves psychotherapy, medication or both, with brain stimulation therapy as an option when those do not reduce symptoms enough[1]. Finding the right treatment may take trial and error[1].
Many people do get well. In 2025, 69.4% of U.S. adults who said they had ever had a mental health problem considered themselves in recovery or recovered, according to the National Survey on Drug Use and Health[12]. That question covers all mental health problems, not depression alone, and recovery is self-defined.
Depression can also return after it lifts, which is why guidelines treat staying well as its own phase of care. Long-term course data are reviewed in our analysis of whether depression is chronic.
Remission vs. response
In depression trials, response usually means a drop of at least 50% on a symptom rating scale. Remission means the score falls below a set cutoff; in the STAR*D trial protocol, that was a score below 8 on the Hamilton Rating Scale for Depression[7]. A relapse is a return of symptoms after improvement.
Related Terms
Source: Pigott et al., BMJ Open, 2023
How Is Depression Treated? First-Line Options in U.S. Guidelines
Two U.S. guidelines set out the first step. The American Psychological Association's 2019 guideline recommends seven psychotherapies for adults: behavioral therapy, cognitive therapy, cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), mindfulness-based cognitive therapy (MBCT), psychodynamic therapy and supportive therapy[2]. It also recommends a second-generation antidepressant, meaning an SSRI, SNRI or NDRI[2].
The 2022 VA/DoD guideline gives a strong recommendation that uncomplicated major depressive disorder be treated with either psychotherapy or medication alone, based on patient preference[3]. For a first medication it lists bupropion, mirtazapine, an SNRI, trazodone, vilazodone, vortioxetine or an SSRI, in no ranked order[3].
Severity shifts the starting point. NIMH notes that psychotherapy is often tried first for milder depression, while people with moderate or severe depression are usually prescribed medication as part of the initial plan[1].
VA/DoD suggests combining medication and psychotherapy when depression is severe (a PHQ-9 score above 20), has lasted more than two years, or has recurred two or more times[3]. It also suggests exercise such as yoga, resistance training or aerobics as an add-on to other treatment[3].
Courses differ in length. APA lists 6 to 20 weekly sessions for CBT, 16 to 20 for IPT and eight weekly two-hour group sessions for MBCT[2]. Trial results for CBT are covered in our review of CBT for depression, and drug classes and side effects in anti-depression meds.
Depression Treatments and Where Guidelines Place Them
| Treatment | When it is used | Basis |
|---|---|---|
| Psychotherapy (CBT, IPT, behavioral and others) | First-line, alone or with medication | APA 2019; VA/DoD 2022 (strong) |
| Second-generation antidepressant | First-line, alone or with therapy | APA 2019; VA/DoD 2022 (strong) |
| Medication plus psychotherapy | Severe, persistent (2+ years) or recurrent depression | VA/DoD 2022 (weak for) |
| Exercise | Add-on to other treatment | VA/DoD 2022 (weak for) |
| Repetitive TMS | After partial or no response to 2+ medication trials | VA/DoD 2022 (weak for) |
| Esketamine or ketamine | After several medication trials | VA/DoD 2022 (weak for); FDA label 2025 |
| Electroconvulsive therapy | Severe depression with psychosis, catatonia, severe suicidality or need for rapid response | VA/DoD 2022 (strong) |
| Continued antidepressant | At least 6 months after remission | VA/DoD 2022 (strong) |
1"Strong" and "weak for" are the VA/DoD guideline's own recommendation strengths[3].
2The FDA label covers esketamine nasal spray (Spravato)[9]. Intravenous ketamine's FDA approvals are as a sedative, analgesic and general anesthetic[8].
Sources
- •APA, 2019
- •VA/DoD, 2022
- •FDA, 2025
Therapy, Medication or Both: How Well Each Works
Antidepressants outperform placebo on average. A 2018 network meta-analysis of 522 trials with 116,477 participants found all 21 antidepressants studied were more effective than placebo, with odds ratios for response from 1.37 for reboxetine to 2.13 for amitriptyline[4]. The authors rated the certainty of the evidence as moderate to very low[4].
No single drug stands out enough to be a default. APA's guideline concluded the evidence was insufficient to recommend any specific second-generation antidepressant over another[2].
Psychotherapy alone and medication alone performed about the same in a 2020 network meta-analysis of 101 studies with 11,910 patients (relative risk of response 0.99)[5]. Combining them did better: response was 27% more likely than with psychotherapy alone and 25% more likely than with medication alone[5].
Remission followed the same pattern, with combined treatment 22% to 23% more likely to produce remission than either single treatment[5]. These are averages across trials and do not predict which option a given person will respond to.
Timing matters when judging whether a treatment works. NIMH says antidepressants usually take 4 to 8 weeks, and sleep, appetite and concentration often improve before mood[1]. In STAR*D, participants who reached remission needed nearly seven weeks of treatment on average to get there[6].
Higher likelihood of response with medication plus psychotherapy than with medication alone
Across 101 randomized trials of adult depression, psychotherapy alone and medication alone produced similar response rates. Combining the two raised the relative likelihood of response (RR 1.25 vs. medication alone; RR 1.27 vs. psychotherapy alone).
"combined treatment was more effective than psychotherapy alone (RR=1.27) and pharmacotherapy alone (RR=1.25)"
What Happens When the First Treatment Does Not Work?
A first treatment is often not enough. In the NIMH-funded STAR*D trial, about one-third of participants reached remission on the first medication, citalopram, and about half had become symptom-free after two treatment levels[6].
Those figures are contested. A 2023 reanalysis using the trial's protocol-specified rating scale put cumulative remission after four steps at 35.0%, against the 67% originally reported[7]. Dropout also rose at each level, from 21% after level 1 to 42% after level 3[6].
The step-by-step numbers are broken down in how to get out of depression.
NIMH defines treatment-resistant depression as not getting better after trying at least two antidepressants[1]. Options at that stage include adding a different type of medication, such as an antipsychotic or anticonvulsant, as well as rapid-acting drugs and brain stimulation[1].
Esketamine and ketamine
Esketamine nasal spray (Spravato) is FDA-approved for treatment-resistant depression in adults, and its January 2025 label allows use alone or with an oral antidepressant[9]. It is given under a health care provider's supervision through a restricted program, with monitoring for at least two hours after each dose for sedation, dissociation and breathing effects[9].
VA/DoD suggests ketamine or esketamine as an add-on option for people who have not responded to several adequate medication trials[3]. In a 2023 trial of 403 patients with nonpsychotic treatment-resistant depression, 55.4% responded to intravenous ketamine and 41.2% to ECT over the initial treatment phase, meeting the trial's test that ketamine was not worse[8].
Electroconvulsive therapy and TMS
VA/DoD strongly recommends offering electroconvulsive therapy (ECT) in severe depression with catatonia, psychotic features or severe suicidality, when a rapid response is needed, or after poor response to multiple antidepressants[3]. In the ketamine comparison trial, ECT was associated with larger declines on memory tests[8]. More detail is in our ECT explainer.
Repetitive transcranial magnetic stimulation (rTMS) is suggested after partial or no response to two or more adequate medication trials[3]. Its trial results are reviewed in TMS treatment for depression.
Does Depression Come Back After Treatment?
Relapse is common enough that guidelines build continuation into treatment. VA/DoD strongly recommends continuing an antidepressant at the therapeutic dose for at least six months after remission to lower the risk of relapse[3].
A UK trial tested what happens after longer use. Among 478 primary care patients who felt well enough to consider stopping long-term antidepressants, 56% of those assigned to discontinue relapsed within 52 weeks, compared with 39% of those who kept taking them[10].
Psychological relapse prevention also has trial support. An individual patient data meta-analysis of 9 trials with 1,258 patients found MBCT was associated with a lower risk of relapse over 60 weeks than no MBCT (hazard ratio 0.69) and than other active treatments, including antidepressants (hazard ratio 0.79)[11].
Those MBCT trials enrolled people with recurrent depression who were already in full or partial remission[11]. The evidence speaks to keeping depression away after treatment, not to treating a current episode.
Outcomes at Each Stage of Treatment in Key Studies
| Stage | Study | Result |
|---|---|---|
| First medication | STAR*D, citalopram | About 1 in 3 reached remission |
| First-line comparison | Cuijpers 2020, 101 trials | Therapy vs. medication RR 0.99; combined vs. medication RR 1.25 |
| Treatment-resistant | Anand 2023, ketamine vs. ECT | Response 55.4% vs. 41.2% |
| Staying well on medication | Lewis 2021, ANTLER | Relapse by 52 weeks: 39% continued vs. 56% stopped |
| Relapse prevention therapy | Kuyken 2016, 9 MBCT trials | Relapse hazard ratio 0.69 vs. no MBCT |
Selected results from trials and meta-analyses at each stage of depression treatment in adults[6][5][8][10][11].
1Response and remission definitions differ between studies, so rows are not directly comparable[7].
Sources
- •NIMH
- •World Psychiatry, 2020
- •NEJM, 2023
- •NEJM, 2021
- •JAMA Psychiatry, 2016
How Many People With Depression Get Treated?
Treatment only helps the people who receive it. Of the estimated 19.7 million U.S. adults with a past-year major depressive episode in 2025, 65.9% received some form of mental health treatment, according to NSDUH[12].
Among those adults, 51.7% took prescription medication for their mental health, 47.6% received outpatient care and 44.7% used telehealth[12]. About one-third received no mental health treatment that year[12].
Young adults were the least likely to be treated: 59.1% of those aged 18 to 25 with a past-year episode received treatment, compared with 68.6% of adults aged 26 to 49[12]. Rates by state and population are on the depression statistics page, and barriers to care are covered in the mental health treatment gap.
Frequently Asked Questions
Sources & References
- National Institute of Mental Health. Depression. National Institutes of Health. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/publications/depression [Link]
- American Psychological Association. Depression Treatments for Adults. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. American Psychological Association. Published 2019. Accessed October 2026. https://www.apa.org/depression-guideline/adults [Link]
- U.S. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder: Provider Summary, Version 4.0. U.S. Department of Veterans Affairs and Department of Defense. Published 2022. Accessed October 2026. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPG_ProviderSummary_Final_508_updated.pdf [Link]
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. Published 2018. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext [Link]
- Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. Published 2020. Accessed October 2026. https://onlinelibrary.wiley.com/doi/full/10.1002/wps.20701 [Link]
- National Institute of Mental Health. Questions and Answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study: All Medication Levels. National Institutes of Health. Published 2006. Accessed October 2026. https://www.nimh.nih.gov/funding/clinical-research/practical/stard/allmedicationlevels [Link]
- Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol. BMJ Open. Published 2023. Accessed October 2026. https://bmjopen.bmj.com/content/13/7/e063095 [Link]
- Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine. Published 2023. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa2302399 [Link]
- U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray, CIII: Highlights of Prescribing Information. U.S. Food and Drug Administration. Published 2025. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf [Link]
- Lewis G, Marston L, Duffy L, et al. Maintenance or discontinuation of antidepressants in primary care. New England Journal of Medicine. Published 2021. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa2106356 [Link]
- Kuyken W, Warren FC, Taylor RS, et al. Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: an individual patient data meta-analysis from randomized trials. JAMA Psychiatry. Published 2016. Accessed October 2026. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2517515 [Link]
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2025 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. Published 2026. Accessed October 2026. https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-report.pdf [Link]